| Original language | English (US) |
|---|---|
| Pages (from-to) | 446-448 |
| Number of pages | 3 |
| Journal | Clinical Journal of the American Society of Nephrology |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2021 |
ASJC Scopus subject areas
- Epidemiology
- Critical Care and Intensive Care Medicine
- Nephrology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Preliminary assessment of acute kidney injury in critically ill children associated with SARS-CoV-2 infection : A multicenter cross-sectional analysis. / The SPARC Investigators.
In: Clinical Journal of the American Society of Nephrology, Vol. 16, No. 3, 03.2021, p. 446-448.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Preliminary assessment of acute kidney injury in critically ill children associated with SARS-CoV-2 infection
T2 - A multicenter cross-sectional analysis
AU - The SPARC Investigators
AU - Bjornstad, Erica C.
AU - Krallman, Kelli A.
AU - Askenazi, David
AU - Zappitelli, Michael
AU - Goldstein, Stuart L.
AU - Basu, Rajit K.
N1 - Funding Information: Our centralized data collection is housed at Cincinnati Children’s Hospital Medical Center via grant support from the Center for Clinical and Translational Science and Training (2UL1TR001425-05A1). Funding Information: D. Askenazi reports consultancy agreements with AKI Foundation, Baxter, Bioporto, Inc., CHF Solutions, and Medtronic and receiving research funding from Baxter Renal Products and CHF Solutions. R.K. Basu reports consultancy agreements with Baxter Healthcare Solutions, BD, Biomerieux, BioPorto Diagnostics, and Potrero and speakers bureau for Baxter and BioPorto Diagnostics. E.C. Bjornstad reports that Bioporto, Inc. provided free supplies for a past research project in Malawi (using their NGALds dipstick). S.L. Goldstein reports consultancy agreements with Baxter Healthcare, Bioporto, Inc., CHF Solutions, Fresenius, Kaneka, Inc., La Jolla Pharmaceuticals, MediBeacon, Medtronic, Otsuka, Reata, and Re-nibus; ownership interest in MediBeacon; receiving research funding from Baxter Healthcare, Bioporto, Inc., and CHF Solutions; receiving honoraria from Baxter Healthcare and Fresenius; patents and inventions with Vigilanz; serving as a scientific advisor or member of MediBeacon; and speakers bureau for Baxter Healthcare and Fresenius. M. Zappitelli reports consultancy agreements with Bioporto, Inc., CytoPheryx Inc., and Eloxx Pharmaceuticals; receiving honoraria from Bioporto, Inc. and Eloxx Pharmaceuticals; and other interests/ relationships with the Canadian Pediatric Nephrologists Association, the Canadian Society of Nephrology, and the Kidney Foundation of Canada. The remaining author has nothing to disclose. Funding Information: Grant support was provided by National Institutes of Health grant 2UL1TR001425-05A1. Our centralized data collection is housed at Cincinnati Children?s Hospital Medical Center via grant support from the Center for Clinical and Translational Science and Training (2UL1TR001425-05A1).
PY - 2021/3
Y1 - 2021/3
UR - http://www.scopus.com/inward/record.url?scp=85100574289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100574289&partnerID=8YFLogxK
U2 - 10.2215/CJN.11470720
DO - 10.2215/CJN.11470720
M3 - Letter
C2 - 33144276
AN - SCOPUS:85100574289
SN - 1555-9041
VL - 16
SP - 446
EP - 448
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
IS - 3
ER -